Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Eli Lilly's launch of ruboxistaurin in 2006 will transform the diabetic neuropathy drug market from a focus on pain control to one of disease modification.

According to the new Pharmacor study entitled Diabetic Neuropathy, Eli Lilly's ruboxistaurin promises to be the first drug with disease-modifying potential that will launch beyond Japan. (Epalrestat, available in Japan since 1995, is thought by physicians to be only moderately effective.)

"Although ruboxistaurin has performed poorly in trials for diabetic retinopathy, interviewed experts remain hopeful that, if this agent is administered early enough in the disease process, it will reduce disease progression of distal symmetrical polyneuropathy, the most common clinical manifestation of neuropathy among diabetics," said Carilee Berg, Ph.D., analyst at Decision Resources.

About Diabetic Neuropathy

Diabetic neuropathy is a disease in which diabetics' hyperglycemia leads to nerve damage. Distal symmetrical polyneuropathy, also known as diabetic peripheral neuropathy, is the most common clinical manifestation of neuropathy among diabetics. Symptoms include pain and numbness, and the disease can lead to ulcers and even amputation. Distal symmetrical polyneuropathy patients are currently treated with drugs to control pain.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Despite Patent Expiry of Key Antibiotics, the Community-Acquired Pneumonia Drug Market Will Be Supported by the Uptake of New Therapies

View Now